Table 4. EGFR G465R and S492R ectodomain mutations and also KRAS and NRAS mutations after EGFR antibody treatment in circulating tumor DNA from the "liquid biopsy” patient cohort.*.
| pat # | category | G465R mutation | S492R mutation | KRAS (ex. 2/3/4) | NRAS (ex. 2/3/4) |
|---|---|---|---|---|---|
| 22 | panitumumab group | wt | wt | wt | wt |
| 23 | wt | wt | wt | wt | |
| 24 | wt | wt | wt | wt | |
| 25 | G465R (7.7%) | wt | wt | wt | |
| 26 | wt | wt | wt | wt | |
| 27 | wt | wt | wt | wt | |
| 28 | cetuximab group | wt | wt | cod. 12 (GaV,3.6%) | wt |
| 29 | wt | wt | wt | wt | |
| 30 | wt | wt | wt | wt | |
| 31 | wt | wt | wt | wt | |
| 32 | wt | wt | wt | wt | |
| 33 | wt | wt | wt | wt | |
| 34 | wt | wt | wt | wt | |
| 35 | wt | wt | wt | wt | |
| 36 | wt | wt | cod. 12 (G->V. 10.4%) | wt | |
| 37 | wt | wt | cod. 12 (G->V. 5.7%) | wt | |
| 38 | wt | wt | wt | wt | |
| 39 | wt | wt | cod. 61 (Q->I1. 4.8%) | wt | |
| 40 | wt | wt | wt | wt | |
| 41 | wt | M | wt | wt | |
| 42 | wt | wt | cod. 12 (G->V. 1.1%) | wt | |
| 43 | wt | wt | cod. 12 (G->V. 3.2%) | wt | |
| 44 | control group (w/o EGFR targeted therapy) | wt | wt | wt | wt |
| 45 | wt | wt | exon 2 (n.s.) | wt | |
| 46 | wt | wt | cod. 12 (G->D. 1.1%) | wt | |
| 47 | wt | wt | cod. 12 (G->V. 3.8%) | wt | |
| 48 | wt | wt | cod. 12 (G->V. 25.0%) | wt | |
| 49 | healthy control | wt | wt | wt | wt |
*
wt = wild-type;
cod. = codon; n.s. = not specified; % = percentage of reads